Duodenal infusion of donor feces for recurrent Clostridium difficile infection A French experience

Size: px
Start display at page:

Download "Duodenal infusion of donor feces for recurrent Clostridium difficile infection A French experience"

Transcription

1 Duodenal infusion of donor feces for recurrent Clostridium difficile infection A French experience Benoit Guery Unité des Maladies Infectieuses CHRU - Faculté de Médecine Lille

2 Conflicts of interest Conferences, Board, Research, Meeting, pencils. Pfizer Astellas Aromathérapie Creative antibiotics Sanofi Pasteur Glycomimetics Lesaffre

3 Almost poetry. «Re-establish the balance of nature» Eiseman 1958

4 CDI infection Microbiota Risks factors: Clindamycine, Cephalosporins, Fluoroquinolones Hospitalisation Age Spores Germination Multiplication vegetatives cells Colonisation Toxins Production Clinical symptoms

5 (1) Local production of toxins A and B leads to production of tumour necrosis factor-alpha and proinflammatory interleukins, increased vascular permeability, neutrophil and monocyte recruitment (2) opening of epithelial cell junctions (3) epithelial cell apoptosis (4) Local production of hydrolytic enzymes leads to connective tissue degradation, leading to colitis, pseudomembrane formation (5) and watery diarrhea.

6 Two large toxins, toxin A and toxin B (TcdA and TcdB), are encoded on the pathogenicity locus (PaLoc), which comprises five genes. A third toxin, the binary toxin or CDT, is encoded on a separate region of the chromosome (CdtLoc) and comprises three genes.

7 Vancomycin, Metronidazole, Fidaxomicin, Rifamixin, Nitazoxanide, SMT Tolevamer Ig, monoclonal Ab, Vaccine Probiotics, S boulardii,.

8 Quantitative pyrosequencing of the microbiota defined a core measurable microbiota (CMM) of 64 conserved taxonomic groups that varied quantitatively across most animals in the population by National Academy of Sciences Benson A K et al. PNAS 2010;107:

9 Microbiota

10 Ampicillin (1 g/l), vancomycin (500 mg/l), neomycin sulfate (1 g/l), and metronidazole (1 g/l) in drinking water for 4 wk before PR8 virus infection (10 pfu per mouse). Proc Natl Acad Sci USA 2011

11 Molasses flies preferred to mate with other molasses flies and starch flies preferred to mate with other starch flies Antibiotic treatment abolished mating preference, suggesting that the fly microbiota was responsible for the phenomenon. Analytical data suggest that symbiotic bacteria can influence mating preference by changing the levels of cuticular hydrocarbon sex pheromones

12

13 (4) The 16S sequences of all patients in each group were pooled (3) (3) Compared with those from control subjects and patients with an initial episode, the fecal communities in patients with recurrent CDAD were highly variable in bacterial composition and were characterized by markedly decreased diversity.

14 So finally Infectious Diseases doctor can transplant..

15

16

17

18 Debast SB, et al. Clin Microbiol Infect 2014;20(Suppl 2):1 26.

19 Study Population >18 years of age Relapse of C. difficile infection after at least one course of adequate antibiotic therapy C. difficile infection was defined as diarrhea ( 3 loose or watery stools per day for at least 2 consecutive days or 8 loose stools in 48 hours) and a positive stool test for C. difficile toxin.

20 Groups Vancomycin followed by bowel lavage and the infusion of a suspension of donor feces through a nasoduodenal tube the next day Vancomycin regimen Vancomycin regimen with bowel lavage on day 4 or 5. Second infusion with feces from a different donor if recurrence. Patients in whom antibiotic therapy failed were offered treatment with donor feces off protocol.

21

22

23 Fecal samples were collected from 10 patients undergoing fecal bacteriotherapy Bacterial populations in patient fecal samples were followed from pretreatment to 24 weeks post-initial infusion At intervals of 4, 8, and 24 weeks after the procedure, the bacterial populations in the patients' fecal samples consisted predominantly of bacteria derived from the healthy donor samples. This study demonstrates a durable beneficial change in the patients' bacterial populations of the colon to represent those of the healthy donor's microbiota. J Clin Gastroenterol Sep 44(8):

24 A multicenter long-term follow-up study was performed on the use of FMT in hospitalized pts with severe or complicated CDI. CDI was defined as severe in the presence of abdominal tenderness, albumin < 3.0 g/dl or WBC >15,000 cells/μl and as complicated if there was admission to the intensive care unit (as a consequence of CDI); hypotension with or without the use of vasopressors; change in mental status; WBC>35,000 cells/μl or <2,000 cells/μl; serum lactate levels 2.2 mmol/l; end-organ failure; fever 38.5 C; ileus or significant abdominal tenderness. 13 eligible pts identified. Gastroenterology 2013;144: S-185.

25 All pts were hospitalized at the time of FMT and diagnosed with severe (84%) or complicated CDI (92%). After FMT, diarrhea resolved in 9 pts (75%) within 1-7 days (mean: 4.5 days) and improved in the remaining 3 pts (25%). Primary cure rate was 84%. Secondary cure rate was 92%. Late CDI recurrence ( 90 days) after FMT was seen in 1 of 13 pts (8%) in association with antibiotic treatment of diverticulitis. FMT is a successful treatment option in pts with severe or complicated CDI. Gastroenterology 2013;144: S-185.

26 Case reports

27 Adverse events Amsterdam 200 fecal transplantation procedures, Sydney more than 3000 without any serious adverse events diarrhea on the day of infusion, a small percentage report belching and/or abdominal cramping or constipation. In another case report, nasoduodenal FMT for Crohn s disease resulted in transient adverse effects, including fever and abdominal tenderness in 3 of 4 patients. Long-term follow-up studies have found that FMT is relatively free of adverse effects Am J Gastroenterol 2012;107:

28

29

30

31 Let s do it!

32 Legal issues Microbiota transplantation=drug Under the pharmacist s responsability Authorization for clinical trials Screening of the donors March 2014

33 Perfect donor yo BMI<30 No chronic disease No current treatment No antibiotics within the last 3 months No foreign travel within the last 3 months No residency in tropical areas No admission in foreign hospitals within the last 12 months No diarrhea within the last 3 months No typhoid Normal aspect of the feces Negative tests for infectious pathogens

34 Parasites Virus Bacteria Screening Blood Treponema pallidum HIV HTLV Hepatitis A B C E CMV/EBV S stercoralis T gondii Trichinella sp Feces C difficile L monoctygenes V cholerae/parahemolyticus Salmonella Shigella MDR pathogens Adenovirus Astrovirus Cacivirus Picornavirus Rotavirus S stercoralis Cryptosporidium sp Cyclospora sp E histolytica G intestinalis Isospora sp Microsporidies

35 «A good movie is better than 25 lousy slides» late) (And time is running and I m probably already

36 This movie will not candidate for the oscars

37

38

39 Fecal microbiome transplantation (FMT) via oral fecal microbial capsules for recurrent Clostridium difficile infection (rcdi) 27 patients >3 CDI treated with vanco Tablets from 100g of feces tb to swallow in 5-15 min Tolerance ok Efficacy No recurrence Microbiota modification persisting at 6 month T. Louie IDWeek 2013

40

41

42

Star Articles in Review

Star Articles in Review Star Articles in Review CDDW/CASL Meeting Toronto, February 10, 2014 Christina M. Surawicz, MD MACG Professor of Medicine Division of Gastroenterology Department of Medicine University of Washington Disclosure

More information

All POOPed out: fecal microbiota transplant in C. difficile

All POOPed out: fecal microbiota transplant in C. difficile All POOPed out: fecal microbiota transplant in C. difficile SUSAN M. KELLIE, MD, MPH PROFESSOR OF INTERNAL MEDICINE DIVISION OF INFECTIOUS DISEASES UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE HOSPITAL

More information

Fecal transplantation as a treatment option for recurrent Clostridium difficile infection

Fecal transplantation as a treatment option for recurrent Clostridium difficile infection Fecal transplantation as a treatment option for recurrent Clostridium difficile infection Josbert Keller Department of Gastroenterology Haga Teaching Hospital, The Hague Case: 81 yrs, CVA, recurrent UTI,

More information

Clostridium difficile Infection: Diagnosis and Management

Clostridium difficile Infection: Diagnosis and Management Clostridium difficile Infection: Diagnosis and Management Brian Viviano D.O. Case study 42 year old female with history of essential hypertension and COPD presents to ED complaining of 24 hours of intractable,

More information

Case 1. Which of the following would be next appropriate investigation/s regarding the pts diarrhoea?

Case 1. Which of the following would be next appropriate investigation/s regarding the pts diarrhoea? Case 1 21 yr old HIV +ve, Cd4-100 HAART naïve Profuse diarrhoea for 3/52. Stool MC&S ve Which of the following would be next appropriate investigation/s regarding the pts diarrhoea? Repeat stool MC&S Stool

More information

Nicola Petrosillo Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, IRCCS Roma. L infezione da C difficile grave o complicata

Nicola Petrosillo Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, IRCCS Roma. L infezione da C difficile grave o complicata Nicola Petrosillo Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, IRCCS Roma L infezione da C difficile grave o complicata Bagdasarian N et al. JAMA 2015; 313: 398-408 European Society

More information

Division of GIM Lecture Series Case Presentation David A. Erickson, M.D October 9th, 2013

Division of GIM Lecture Series Case Presentation David A. Erickson, M.D October 9th, 2013 Division of GIM Lecture Series Case Presentation David A. Erickson, M.D October 9th, 2013 Financial Disclosures No financial disclosures Objectives Review a case of recurrent Clostridium difficile infection

More information

What s New for Clostridium difficile John Lynch MD MPH Harborview Medical Center University of Washington

What s New for Clostridium difficile John Lynch MD MPH Harborview Medical Center University of Washington What s New for Clostridium difficile 2013 John Lynch MD MPH Harborview Medical Center University of Washington Pathogenic Mechanisms of Diarrhea Toxins: Preformed: S aureus, C perfringens, B cereus Formed

More information

Clinical Policy Bulletin: Fecal Bacteriotherapy

Clinical Policy Bulletin: Fecal Bacteriotherapy Clinical Policy Bulletin: Fecal Bacteriotherapy Number: 0844 Policy Aetna considers fecal bacteriotherapy medically necessary for persons with Clostridium difficile infection, with infection confirmed

More information

EDUCATIONAL COMMENTARY CLOSTRIDIUM DIFFICILE UPDATE

EDUCATIONAL COMMENTARY CLOSTRIDIUM DIFFICILE UPDATE EDUCATIONAL COMMENTARY CLOSTRIDIUM DIFFICILE UPDATE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits click

More information

9/18/2018. Clostridium Difficile: Updates on Diagnosis and Treatment. Clostridium difficile Infection (CDI) Clostridium difficile Infection (CDI)

9/18/2018. Clostridium Difficile: Updates on Diagnosis and Treatment. Clostridium difficile Infection (CDI) Clostridium difficile Infection (CDI) Clostridium Difficile: Updates on Diagnosis and Treatment Elizabeth Hudson, DO, MPH 9/25/18 Antibiotic-associated diarrhea and colitis were well established soon after widespread use of antibiotics In

More information

Clostridium difficile CRISTINA BAKER, MD, MPH INFECTIOUS DISEASE PARK NICOLLET/HEALTH PARTNERS 11/9/2018

Clostridium difficile CRISTINA BAKER, MD, MPH INFECTIOUS DISEASE PARK NICOLLET/HEALTH PARTNERS 11/9/2018 Clostridium difficile CRISTINA BAKER, MD, MPH INFECTIOUS DISEASE PARK NICOLLET/HEALTH PARTNERS 11/9/2018 Disclosures None Objectives Highlight important changes in the management of Clostridium difficile

More information

Clostridium Difficile Infection: Applying New Treatment Guidelines and Strategies to Reduce Recurrence Rate

Clostridium Difficile Infection: Applying New Treatment Guidelines and Strategies to Reduce Recurrence Rate Clostridium Difficile Infection: Applying New Treatment Guidelines and Strategies to Reduce Recurrence Rate Objectives Summarize the changing epidemiology and demographics of patients at risk for Clostridium

More information

Clostridium difficile Infection (CDI) Management Guideline

Clostridium difficile Infection (CDI) Management Guideline Clostridium difficile Infection (CDI) Management Guideline Do not test all patients with loose or watery stools for CDI o CDI is responsible for

More information

Fecal microbiota transplantation: Breaking the chain of recurrent C. difficile infection

Fecal microbiota transplantation: Breaking the chain of recurrent C. difficile infection Fecal microbiota transplantation: Breaking the chain of recurrent C. difficile infection Issue Date: June 2013 Vol. 8 No. 6 Author: Amy Marinski, MSN, RN, CCRN, CNL More than 3 million new cases of Clostridium

More information

The Epidemiology of Clostridium difficile DANIEL SAMAN, DRPH, MPH RESEARCH SCIENTIST ESSENTIA INSTITUTE OF RURAL HEALTH

The Epidemiology of Clostridium difficile DANIEL SAMAN, DRPH, MPH RESEARCH SCIENTIST ESSENTIA INSTITUTE OF RURAL HEALTH The Epidemiology of Clostridium difficile DANIEL SAMAN, DRPH, MPH RESEARCH SCIENTIST ESSENTIA INSTITUTE OF RURAL HEALTH Some history first Clostridium difficile, a spore-forming gram-positive (i.e., thick

More information

Stony Brook Adult Clostridium difficile Management Guidelines. Discontinue all unnecessary antibiotics

Stony Brook Adult Clostridium difficile Management Guidelines. Discontinue all unnecessary antibiotics Stony Brook Adult Clostridium difficile Management Guidelines Summary: Use of the C Diff Infection (CDI) PowerPlan (Adult) Required Patient with clinical findings suggestive of Clostridium difficile infection

More information

Patient presentation

Patient presentation Update: Clostridium difficile Colitis David H. Kerman, MD Assistant Professor of Clinical Medicine Director, Fellowship Program Division of Gastroenterology University of Miami Miller School of Medicine

More information

Treatment Update on Fecal Microbiota Transplantation. Arnab Ray, MD Ochsner Clinic Foundation Gastroenterology Department

Treatment Update on Fecal Microbiota Transplantation. Arnab Ray, MD Ochsner Clinic Foundation Gastroenterology Department Treatment Update on Fecal Microbiota Transplantation Arnab Ray, MD Ochsner Clinic Foundation Gastroenterology Department Disclosure I serve as a paid medical monitor for Rebiotix Objectives The scope of

More information

Update on Clostridium difficile infection.

Update on Clostridium difficile infection. Update on Clostridium difficile infection. K. Honein Gastroenterologist, HDF Associate Professor Head of Medicine Department St Joseph University-Beirut. Introduction Gram+anaerobic bacillus responsible

More information

Corporate Medical Policy Fecal Microbiota Transplantation

Corporate Medical Policy Fecal Microbiota Transplantation Corporate Medical Policy Fecal Microbiota Transplantation File Name: Origination: Last CAP Review: Next CAP Review: Last Review: Fecal_microbiota_transplantation 7/2014 11/2017 11/2018 11/2017 Description

More information

ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Clostridium difficile Infections

ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Clostridium difficile Infections ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Clostridium difficile Infections Christina M. Surawicz, MD 1, Lawrence J. Brandt, MD 2, David G. Binion, MD 3, Ashwin N. Ananthakrishnan,

More information

Clostridium difficile: Can you smell the new updates?

Clostridium difficile: Can you smell the new updates? Clostridium difficile: Can you smell the new updates? Sunish Shah, Pharm.D. PGY-2 Infectious Disease Pharmacy Resident Yale-New Haven Hospital sshah1741@mail.usciences.edu Learning objectives Recognize

More information

C. difficile: When to Do Fecal Microbiota Transplant (FMT)

C. difficile: When to Do Fecal Microbiota Transplant (FMT) C. difficile: When to Do Fecal Microbiota Transplant (FMT) Lawrence J. Brandt, MD, MACG Emeritus Chief, Gastroenterology Montefiore Medical Center Professor of Medicine and Surgery Albert Einstein College

More information

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics. DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this

More information

Clostridium Difficile colitismore

Clostridium Difficile colitismore Clostridium Difficile colitismore virulent than ever ECHO- February 18, 2016 Charles Krasner, M.D. UNR School of Medicine Sierra NV Veterans Affairs Hospital Growing problem of pseudomembranous colitis

More information

Long-Term Care Updates

Long-Term Care Updates Long-Term Care Updates April 2018 By Austin Smith, PharmD Candidate and Lindsay Slowiczek, PharmD is the most common healthcare-acquired infection (HAI) in the United States. 1,2 A 2014 prevalence survey

More information

FECAL TRANSPLANTATION

FECAL TRANSPLANTATION FECAL TRANSPLANTATION From Theory to Practice in Ridge Meadows Edward Auersperg 13 January 2016 The Human Genome How many different chromosomes do humans have? 46 chromosomes 23 pairs The Human Genome

More information

CLOSTRIDIUM DIFICILE. Negin N Blattman Infectious Diseases Phoenix VA Healthcare System

CLOSTRIDIUM DIFICILE. Negin N Blattman Infectious Diseases Phoenix VA Healthcare System CLOSTRIDIUM DIFICILE Negin N Blattman Infectious Diseases Phoenix VA Healthcare System ANTIBIOTIC ASSOCIATED DIARRHEA 1978: C diff first identified 1989-1992: Four large outbreaks in the US caused by J

More information

DISCLOSURE Relevant relationships with commercial entities Wyeth (received advisory board & speaker honoraria) Potential for conflicts of interest wit

DISCLOSURE Relevant relationships with commercial entities Wyeth (received advisory board & speaker honoraria) Potential for conflicts of interest wit GASTROENTERITIS DISCLOSURE Relevant relationships with commercial entities Wyeth (received advisory board & speaker honoraria) Potential for conflicts of interest within this presentation fidaxomicin (which

More information

more intense treatments are needed to get rid of the infection.

more intense treatments are needed to get rid of the infection. What Is Clostridium Difficile (C. Diff)? Clostridium difficile, or C. diff for short, is an infection from a bacterium that can grow in your intestines and cause bad GI symptoms. The main risk of getting

More information

Clostridium DifficileInfection & Readmissions: An ounce of prevention is worth a pound of cure

Clostridium DifficileInfection & Readmissions: An ounce of prevention is worth a pound of cure Clostridium DifficileInfection & Readmissions: An ounce of prevention is worth a pound of cure Brian S. Zuckerbraun, MD, FACS Henry T. Bahnson Professor of Surgery University of Pittsburgh Chief, Trauma

More information

! MQ is a 44 year old woman that I first saw in Sept ! In MVA in Jan 2003 requiring spinal surgery

! MQ is a 44 year old woman that I first saw in Sept ! In MVA in Jan 2003 requiring spinal surgery Case MQ is a 44 year old woman that I first saw in Sept 2006 UPDATE ON CLOSTRIDIUM DIFFICILE DISEASE Richard A. Jacobs, M.D.,PhD In MVA in Jan 2003 requiring spinal surgery Subsequently developed fecal

More information

ENGLISH FOR PROFESSIONAL PURPOSES UNIT 3 HOW TO DEAL WITH CLOSTRIDIUM DIFFICILE

ENGLISH FOR PROFESSIONAL PURPOSES UNIT 3 HOW TO DEAL WITH CLOSTRIDIUM DIFFICILE ENGLISH FOR PROFESSIONAL PURPOSES UNIT 3 HOW TO DEAL WITH CLOSTRIDIUM DIFFICILE The diagnosis of CDI should be based on a combination of clinical and laboratory findings. A case definition for the usual

More information

Updates to pharmacological management in the prevention of recurrent Clostridium difficile

Updates to pharmacological management in the prevention of recurrent Clostridium difficile Updates to pharmacological management in the prevention of recurrent Clostridium difficile Julia Shlensky, PharmD PGY2 Internal Medicine Resident September 12, 2017 2017 MFMER slide-1 Clinical Impact Increasing

More information

Clostridium difficile

Clostridium difficile Clostridium difficile Alex Aspinall MD, PhD, FRCPC Clinical Assistant Professor, University of Calgary Division of Gastroenterology and Hepatology, South Health Campus www.seacourses.com 1 Learning Points

More information

500,000 29,000. New 2015 Data. Lessa et al, N Eng J Med 2015: 34.2% of CDI cases were considered community-acquired

500,000 29,000. New 2015 Data. Lessa et al, N Eng J Med 2015: 34.2% of CDI cases were considered community-acquired Cost-effective Treatment of Clostridium difficile Infection in the ICU Kevin W. Garey, PharmD, MS. Professor and Chair University of Houston College of Pharmacy New 2015 Data 500,000 29,000 Lessa et al,

More information

Clostridium Difficile Associated Disease. Edmund Krasinski, Jr., D.O., F.A.C.G. Southwest Conference on Medicine 2011

Clostridium Difficile Associated Disease. Edmund Krasinski, Jr., D.O., F.A.C.G. Southwest Conference on Medicine 2011 Clostridium Difficile Associated Disease Edmund Krasinski, Jr., D.O., F.A.C.G. Southwest Conference on Medicine 2011 Introduction Which of the following is more common in community hospitals in the Southeast

More information

Clinical Review Criteria Fecal Microbial Transplant for Treatment of C. Difficile Infection Fecal GI Infusion Fecal Capsule (G3 OpenBiome)

Clinical Review Criteria Fecal Microbial Transplant for Treatment of C. Difficile Infection Fecal GI Infusion Fecal Capsule (G3 OpenBiome) Clinical Review Criteria Fecal Microbial Transplant for Treatment of C. Difficile Infection Fecal GI Infusion Fecal Capsule (G3 OpenBiome) Criteria Codes Revision History Kaiser Foundation Health Plan

More information

Is FMT the answer? Challenging Cases in CDI. Ted Steiner, M.D. April 1, 2016

Is FMT the answer? Challenging Cases in CDI. Ted Steiner, M.D. April 1, 2016 Is FMT the answer? Challenging Cases in CDI Ted Steiner, M.D. April 1, 2016 CONFLICT OF INTEREST DISCLOSURE SLIDE In the past 2 years I have been an employee of: In the past 2 years I have been a consultant

More information

Patient Safety Summit 2014

Patient Safety Summit 2014 Patient Safety Summit 2014 The War on C Diff Mark Mellow, MD + C Diff The Organism Gram + bacillus Anaerobic Spore forming Intestinal flora (up to 35% hospitalized patients, 3% of healthy adults) Leading

More information

Updated Clostridium difficile Treatment Guidelines

Updated Clostridium difficile Treatment Guidelines Updated Clostridium difficile Treatment Guidelines Arielle Arnold, PharmD, BCPS Clinical Pharmacist Saint Alphonsus Regional Medical Center September 29 th, 2018 Disclosures Nothing to disclose Learning

More information

Responders as percent of overall members in each category: Region: New England 50 (57% of 87 members) 46 (57% of 81 members) 21 (55% of 38 members)

Responders as percent of overall members in each category: Region: New England 50 (57% of 87 members) 46 (57% of 81 members) 21 (55% of 38 members) Infectious Diseases Society of America Emerging Infections Network Report for Query: Recurrent C. difficile Infections (CDI) Overall response rate: 621/1212 (51.2%) physicians responded from 09/26/12 to

More information

Bacterial Therapy: Fecal Transplants, Probiotics and Non-Toxigenic Clostridium difficile for Clostridium difficile Infection (CDI) Management

Bacterial Therapy: Fecal Transplants, Probiotics and Non-Toxigenic Clostridium difficile for Clostridium difficile Infection (CDI) Management Bacterial Therapy: Fecal Transplants, Probiotics and Non-Toxigenic Clostridium difficile for Clostridium difficile Infection (CDI) Management Dale N. Gerding, MD, MACP Professor of Medicine Loyola University

More information

OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA

OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition Joint Session with ACOFP and Cleveland

More information

Managing Clostridium Difficile: An Old Bug With

Managing Clostridium Difficile: An Old Bug With 932 The Red Section see related editorial on page x Managing Clostridium Difficile: An Old Bug With New Tricks Stephen M. Vindigni, MD, MPH 1,2 and Christina M. Surawicz, MD 1 Am J Gastroenterol (2018)

More information

Clostridium difficile infection (CDI) Week 52 (Ending 30/12/2017)

Clostridium difficile infection (CDI) Week 52 (Ending 30/12/2017) Clostridium difficile infection (CDI) Week 52 (Ending 30/12/2017) What is Clostridium difficile? Clostridium difficile is a Gram-positive anaerobic spore forming bacillus. It is ubiquitous in nature and

More information

When To Do Fecal Microbiota Transplant (FMT) For C. difficile

When To Do Fecal Microbiota Transplant (FMT) For C. difficile When To Do Fecal Microbiota Transplant (FMT) For C. difficile Lawrence J. Brandt, MD, MACG Emeritus Chief, Gastroenterology Montefiore Medical Center Professor of Medicine and Surgery Albert Einstein College

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Juul FE, Garborg K, Bretthauer M, et al. Fecal microbiota transplantation

More information

The Potential For Microbiome Modification In Critical Illness. Deborah Cook

The Potential For Microbiome Modification In Critical Illness. Deborah Cook The Potential For Microbiome Modification In Critical Illness Deborah Cook To review Objectives The microbiome & concepts about its modification during critical illness Interventions Predisposition to

More information

Bezlotoxumab (Zinplava) as Adjunct Treatment for Clostridium difficile. Janel Liane Cala, RPh Medical Center Hospital

Bezlotoxumab (Zinplava) as Adjunct Treatment for Clostridium difficile. Janel Liane Cala, RPh Medical Center Hospital Bezlotoxumab (Zinplava) as Adjunct Treatment for Clostridium difficile Janel Liane Cala, RPh Medical Center Hospital Objectives Review pathophysiology, risk factors, prevention, and treatment options of

More information

Journey to Decreasing Clostridium Difficile and the Unexpected Twist. Jackie Morton, Infection Prevention Cortney Swiggart, Medication Safety Officer

Journey to Decreasing Clostridium Difficile and the Unexpected Twist. Jackie Morton, Infection Prevention Cortney Swiggart, Medication Safety Officer Journey to Decreasing Clostridium Difficile and the Unexpected Twist Jackie Morton, Infection Prevention Cortney Swiggart, Medication Safety Officer 4/13/2018 Objectives Discuss the organism and clinical

More information

Fecal Microbiota Transplantation in C. diff. colitis Benefits and Limitations

Fecal Microbiota Transplantation in C. diff. colitis Benefits and Limitations January 27th 2017, 8th Gastro Foundation Weekend for Fellows; Spier Hotel & Conference Centre, Stellenbosch Fecal Microbiota Transplantation in C. diff. colitis Benefits and Limitations Gerhard Rogler,

More information

Disclosure. Objectives. Assessment Questions. History. Clinical Case 2/27/2015. Clostridium difficile update and new therapies

Disclosure. Objectives. Assessment Questions. History. Clinical Case 2/27/2015. Clostridium difficile update and new therapies Disclosure Clostridium difficile update and new therapies Corey Frederick, PharmD PGY-2 Pharmacy Resident, Infectious Diseases Jackson Memorial Hospital Miami, Florida I do not have a vested interest in

More information

Updates in Fecal Microbial Transplant

Updates in Fecal Microbial Transplant Updates in Fecal Microbial Transplant Dina Kao, MD FRCPC Associate Professor, Gastroenterology University of Alberta Nikhil Pai, MD FAAP FRCPC Assistant Professor, Ped Gastroenterology McMaster University

More information

Fecal Microbiota Transplantation. Description

Fecal Microbiota Transplantation. Description Section: Medicine Effective Date: April 15, 2017 Original Policy Date: September 12, 2014 Subject: Fecal Microbiota Transplantation Page: 1 of 10 Last Review Status/Date: March 2017 Fecal Microbiota Transplantation

More information

Title: Fecal microbiota transplantation in recurrent Clostridium difficile infection in a patient with concomitant inflammatory bowel disease

Title: Fecal microbiota transplantation in recurrent Clostridium difficile infection in a patient with concomitant inflammatory bowel disease Title: Fecal microbiota transplantation in recurrent Clostridium difficile infection in a patient with concomitant inflammatory bowel disease Authors: Marta Gravito-Soares, Elisa Gravito-Soares, Francisco

More information

Literature Scan: Antibiotics for Clostridium difficile Infection. Month/Year of Review: May 2015 Date of Last Review: April 2012

Literature Scan: Antibiotics for Clostridium difficile Infection. Month/Year of Review: May 2015 Date of Last Review: April 2012 Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Gut bugs and health. Patrick Bateson

Gut bugs and health. Patrick Bateson Gut bugs and health Patrick Bateson Characteristic odour of kin group is produced by inherited bacterial flora degrading fats secreted by anal glands An increasing number of people in developed countries

More information

Update on C. difficile: Diagnosis and Therapy Including Fecal Transplant

Update on C. difficile: Diagnosis and Therapy Including Fecal Transplant Update on C. difficile: Diagnosis and Therapy Including Fecal Transplant Colleen R. Kelly, MD Clinical Assistant Professor of Medicine Brown University Warren Alpert School of Medicine Rhode Island Chapter,

More information

Fecal Microbiota Transplantation: Clinical and experimental studies van Nood, E.

Fecal Microbiota Transplantation: Clinical and experimental studies van Nood, E. UvA-DARE (Digital Academic Repository) Fecal Microbiota Transplantation: Clinical and experimental studies van Nood, E. Link to publication Citation for published version (APA): van Nood, E. (2015). Fecal

More information

The Netherlands Donor Feces Bank a. it takes stool to get better

The Netherlands Donor Feces Bank a. it takes stool to get better The Netherlands Donor Feces Bank a it takes stool to get better H.W. Verspaget Dept. of Biobanking and Dept. of Gastroenterology Leiden University Medical Center The Netherlands Fecal MicrobiotaTransplantation

More information

The good, the bad and the ugly. Our microbiome and it s effect on health and disease.

The good, the bad and the ugly. Our microbiome and it s effect on health and disease. The good, the bad and the ugly Our microbiome and it s effect on health and disease. Objectives Discuss C difficile infection including treatment options Explain process of Fecal MicrobiotaTransplantation

More information

Terapia dell infezione da Clostridium difficile. Massimo Coen I Div Mal Inf AO L Sacco

Terapia dell infezione da Clostridium difficile. Massimo Coen I Div Mal Inf AO L Sacco Terapia dell infezione da Clostridium difficile Massimo Coen I Div Mal Inf AO L Sacco Disease Severity Mild CDI 3 5 BM/day WBC 15,000/mm 3 Defining CDI Disease Severity Mild abdominal pain due to CDI Moderate

More information

Gut Microbiota Transplant Pro Position. Christina Surawicz, MD, MACG Professor of Medicine University of Washington Seattle WA

Gut Microbiota Transplant Pro Position. Christina Surawicz, MD, MACG Professor of Medicine University of Washington Seattle WA Gut Microbiota Transplant Pro Position Christina Surawicz, MD, MACG Professor of Medicine University of Washington Seattle WA My Focus Recurrent Clostridium difficile infection No uniformly successful

More information

DETECTION OF TOXIGENIC CLOSTRIDIUM DIFFICILE

DETECTION OF TOXIGENIC CLOSTRIDIUM DIFFICILE CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS DETECTION OF TOXIGENIC CLOSTRIDIUM DIFFICILE Policy Number: PDS 021 Effective Date:

More information

Fecal Microbiota Transplantation for Severe sepsis and Diarrhea : a Case Report

Fecal Microbiota Transplantation for Severe sepsis and Diarrhea : a Case Report Fecal Microbiota Transplantation for Severe sepsis and Diarrhea : a Case Report Qiurong Li Institute of General Surgery, Jinling Hospital Nanjing Univeristy Gut Microbiota 100 trillion cells 10-fold of

More information

Fecal Microbiota Transplantation

Fecal Microbiota Transplantation Protocol Fecal Microbiota Transplantation (20192) Medical Benefit Effective Date: 10/01/14 Next Review Date: 07/18 Preauthorization Yes Review Dates: 07/14, 07/15, 07/16, 07/17 Preauthorization is required.

More information

Fecal Microbiota Transplantation (FMT): Current Concepts in Clostridium difficile and beyond

Fecal Microbiota Transplantation (FMT): Current Concepts in Clostridium difficile and beyond Fecal Microbiota Transplantation (FMT): Current Concepts in Clostridium difficile and beyond Amir Patel, MD Assistant Professor of Medicine Froedtert Hospital and the Medical College of Wisconsin I have

More information

Microbiome in You: Optimizing Gut Bacteria for Better IBD Management

Microbiome in You: Optimizing Gut Bacteria for Better IBD Management Microbiome in You: Optimizing Gut Bacteria for Better IBD Management KT Park, M.D., M.S. Assistant Professor Co-Director, Stanford Children s Inflammatory Bowel Disease Center Stanford University School

More information

! Macrolide antibacterial. Fidaxomicin (Dificid ) package labeling. Optimer Pharmaceuticals, Inc. May 2011.

! Macrolide antibacterial. Fidaxomicin (Dificid ) package labeling. Optimer Pharmaceuticals, Inc. May 2011. Disclosure! I have no conflicts of interest related to this presentation Nina Naeger Murphy, Pharm.D., BCPS Clinical Pharmacy Specialist Infectious Diseases MetroHealth Medical Center Learning Objectives!

More information

Hompes Method. Practitioner Training Level II. Lesson Seven Part A DRG Pathogen Plus Interpretation

Hompes Method. Practitioner Training Level II. Lesson Seven Part A DRG Pathogen Plus Interpretation Hompes Method Practitioner Training Level II Lesson Seven Part A DRG Pathogen Plus Interpretation Health for the People Ltd not for reuse without expressed permission Hompes Method is a trading name of

More information

Virtual Lectures Planning Committee Disclosure Summary

Virtual Lectures Planning Committee Disclosure Summary Mayo Medical Laboratories Virtual Lectures 2014 MFMER Virtual Lectures Planning Committee Disclosure Summary As a provider accredited by ACCME, College of Medicine, Mayo Clinic (Mayo School of CPD) must

More information

Faecal Microbiota Transplants: The evidence and experience

Faecal Microbiota Transplants: The evidence and experience Faecal Microbiota Transplants: The evidence and experience Dr Simon Goldenberg Consultant Microbiologist and Infection Control Doctor Guy s & St Thomas NHS Foundation Trust Gut microbiota and health Level

More information

Clostridiodes Difficile Colitis: Update on Guidelines. Jade Le, MD Texas Health Physicians Group No disclosures April 6, 2018

Clostridiodes Difficile Colitis: Update on Guidelines. Jade Le, MD Texas Health Physicians Group No disclosures April 6, 2018 Clostridiodes Difficile Colitis: Update on Guidelines Jade Le, MD Texas Health Physicians Group No disclosures April 6, 2018 Outline Overview of CDI Diagnosis of C Difficile- updates Infection Prevention

More information

Probiotics for Primary Prevention of Clostridium difficile Infection

Probiotics for Primary Prevention of Clostridium difficile Infection Probiotics for Primary Prevention of Clostridium difficile Infection Objectives Review risk factors for Clostridium difficile infection (CDI) Describe guideline recommendations for CDI prevention Discuss

More information

Fecal Microbiota Transplantation

Fecal Microbiota Transplantation Fecal Microbiota Transplantation Policy Number: 2.01.92 Last Review: 7/2018 Origination: 5/2015 Next Review: 7/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for

More information

Common Gastrointestinal Problems in the Elderly

Common Gastrointestinal Problems in the Elderly Common Gastrointestinal Problems in the Elderly Brian Viviano, D.O. Objectives Understand the pathophysiology, clinical manifestations, diagnosis and management of GI diseases of the elderly. Differentiate

More information

Treating and Preventing. C. difficile Infections A Review of the Research for Adults

Treating and Preventing. C. difficile Infections A Review of the Research for Adults Treating and Preventing C. difficile Infections A Review of the Research for Adults e Is This Information Right for Me? This information is right for you if: Your health care professional has said that

More information

An Oral Fecal Transplant for Lunch?- Frankly Speaking EP 53

An Oral Fecal Transplant for Lunch?- Frankly Speaking EP 53 An Oral Fecal Transplant for Lunch?- Frankly Speaking EP 53 Transcript Details This is a transcript of an episode from the podcast series Frankly Speaking accessible at Pri- Med.com. Additional media formats

More information

L infezione da Clostridium difficile (CDI) Quadri clinici e nuovi approcci terapeutici

L infezione da Clostridium difficile (CDI) Quadri clinici e nuovi approcci terapeutici L infezione da Clostridium difficile (CDI) Quadri clinici e nuovi approcci terapeutici Roberto Luzzati SC Malattie Infettive, AOU Trieste Presidente :Prof. Enzo Raise Clinical presentation of infection

More information

Clostridium Difficile Infection in Adults Treatment and Prevention

Clostridium Difficile Infection in Adults Treatment and Prevention Clostridium Difficile Infection in Adults Treatment and Prevention Definition: Clostridium Difficile colonizes the human intestinal tract after the normal gut flora has been altered by antibiotic therapy

More information

Antibiotic Associated Diarrhea (AAD) and Clostridium Difficile Infection (CDI)

Antibiotic Associated Diarrhea (AAD) and Clostridium Difficile Infection (CDI) Antibiotic Associated Diarrhea (AAD) and Clostridium Difficile Infection (CDI) Dario Conte, M.D. Gastroenterology and Endoscopy Unit Postgraduate School of Gastroenterology Fondazione IRCCS Ca Granda Ospedale

More information

Modern approach to Clostridium Difficile Infection

Modern approach to Clostridium Difficile Infection Modern approach to Clostridium Difficile Infection Pseudomembranous Colitis: Principles for diagnosis and treatment Aggelos Stefos Internist, Infectious diseases Specialist Department of Medicine and Research

More information

Clinical Policy Title: Fecal transplantation for clostridium difficile infection

Clinical Policy Title: Fecal transplantation for clostridium difficile infection Clinical Policy Title: Fecal transplantation for clostridium difficile infection Clinical policy number: 08.02.02 Effective Date: October 1, 2014 Initial Review Date: June 18, 2014 Most Recent Review Date:

More information

10/4/2014. The Microbiome vs. the Gastroenterologist. Human Microbiome. Microbiome and Host Physiology: A Delicate Balance

10/4/2014. The Microbiome vs. the Gastroenterologist. Human Microbiome. Microbiome and Host Physiology: A Delicate Balance The Microbiome vs. the Gastroenterologist John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University Human Microbiome Mouth Finlay BB. Scientific American 2010;302:56-63 Microbiome

More information

Pennington Feb 19, 2015

Pennington Feb 19, 2015 Trust your gut Pennington Feb 19, 2015 Crohn s Disease -an autoimmune disorder that causes inflammation of the intestinal tract along with unpredictable, often incapacitating episodes of abdominal pain

More information

New approaches to treating Clostridium difficile Infection

New approaches to treating Clostridium difficile Infection 7:45 8:45 am New Approaches to Treating C. difficile Infection SPEAKER Fred A. Lopez, MD, MACP Presenter Disclosure Information The following relationships exist related to this presentation: Fred A. Lopez,

More information

Clostridium difficile infections Crappy Options

Clostridium difficile infections Crappy Options Clostridium difficile infections Crappy Options Alexandru Petre David MD Infectious Diseases April 21, 2015 Objectives Microbiology Epidemiology Who is at risk? Pathogenesis Diagnosis Treatment Historical

More information

-2002: Rectal blood loss, UC? (no definite diagnosis) rectal mesalazine. -June 2008: Recurrence of rectal blood loss and urgency

-2002: Rectal blood loss, UC? (no definite diagnosis) rectal mesalazine. -June 2008: Recurrence of rectal blood loss and urgency SD, male 40 yrs. old. (680718M467.) -2002: Rectal blood loss, UC? (no definite diagnosis) rectal mesalazine -June 2008: Recurrence of rectal blood loss and urgency Total colonoscopy: ulcerative rectitis,

More information

Does Fecal Microbiota Transplantation Cause Clinical Remission in Patients with Ulcerative Colitis?

Does Fecal Microbiota Transplantation Cause Clinical Remission in Patients with Ulcerative Colitis? Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 12-2017 Does Fecal Microbiota Transplantation

More information

Presenter Disclosure Information

Presenter Disclosure Information 10:45 11:45am New Approaches to Treating C. Difficile Infection SPEAKER Kalpana Gupta, MD, MPH Presenter Disclosure Information The following relationships exist related to this presentation: Kalpana Gupta,

More information

New approaches to treating

New approaches to treating 9:45 10:45am New Approaches to Treating C Difficile Infection SPEAKER Kalpana Gupta, MD, MPH Presenter Disclosure Information The following relationships exist related to this presentation: Kalpana Gupta,

More information

Clostridium difficile Infection (CDI)

Clostridium difficile Infection (CDI) 18.09.10 월요집담회 Clostridium difficile Infection (CDI) R4 송주혜 Clostridium difficile infection (CDI) Anaerobic gram (+), spore-forming, toxin(tcda&tcdb)-producing bacillus Transmitted among humans through

More information

Clostridium difficile infections: Drug treatment re-evaluated

Clostridium difficile infections: Drug treatment re-evaluated Clostridium difficile infections: Drug treatment re-evaluated Kimberly D. Leuthner, PharmD University Medical Center of Southern Nevada August 11, 2016 Random Fact: The human body has 10 13 human cells

More information

declara&ons Clostridium difficile infec&on. Time to wake up and smell the..., um, nevermind. OK, next slide please. Bruce Dalton, BScPhm. PharmD.

declara&ons Clostridium difficile infec&on. Time to wake up and smell the..., um, nevermind. OK, next slide please. Bruce Dalton, BScPhm. PharmD. Clostridium difficile infec&on. Time to wake up and smell the..., um, nevermind. OK, next slide please. Bruce Dalton, BScPhm. PharmD. declara&ons No financial disclosures Personal acquaintance, co- worker,

More information

MEDICAL POLICY SUBJECT: FECAL BACTERIOTHERAPY EFFECTIVE DATE: 08/16/12 REVISED DATE: 08/15/13, 07/17/14, 07/16/15, 06/16/16, 06/15/17

MEDICAL POLICY SUBJECT: FECAL BACTERIOTHERAPY EFFECTIVE DATE: 08/16/12 REVISED DATE: 08/15/13, 07/17/14, 07/16/15, 06/16/16, 06/15/17 MEDICAL POLICY SUBJECT: FECAL BACTERIOTHERAPY PAGE: 1 OF: 7 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including

More information

ABSTRACT PURPOSE METHODS

ABSTRACT PURPOSE METHODS ABSTRACT PURPOSE The purpose of this study was to characterize the CDI population at this institution according to known risk factors and to examine the effect of appropriate evidence-based treatment selection

More information

Zinplava. (bezlotoxumab) New Product Slideshow

Zinplava. (bezlotoxumab) New Product Slideshow Zinplava (bezlotoxumab) New Product Slideshow Introduction Brand name: Zinplava Generic name: Bezlotoxumab Pharmacological class: Human IgG1 monoclonal antibody Strength and Formulation: 25mg/mL; solution

More information

Diagnosis, Management, and Prevention of Clostridium difficile infection in Long-Term Care Facilities: A Review

Diagnosis, Management, and Prevention of Clostridium difficile infection in Long-Term Care Facilities: A Review Diagnosis, Management, and Prevention of Clostridium difficile infection in Long-Term Care Facilities: A Review October 18, 2010 James Kahn and Carolyn Kenney, MSIV Overview Burden of disease associated

More information